Bionano customer praxis genomics accredited by college of american pathologists, completing first ldt in us for constitutional genetic disorders that uses whole genome analysis with saphyr as alternative to chromosomal microarray and karyotyping

San diego, dec. 28, 2020 (globe newswire) -- bionano genomics, inc. (nasdaq: bngo), announced today that praxis genomics, llc received accreditation from the college of american pathologists (cap), making it the first cap-accredited, clia-certified diagnostic lab in the united states to offer a laboratory developed test (ldt) based on whole genome analysis with saphyr. the ldt is designed for postnatal patients suspected of a constitutional genetic disorder. praxis uses optical genome mapping (ogm) with bionano's saphyr system as an alternative to traditional methods of chromosomal microarray (cma) and karyotyping (kt), as they seek to improve the rate of clinical diagnosis for patients with genetic disease. cma and kt together typically diagnose 30-50% of patients tested. recent studies have found that ogm with saphyr is concordant with cma and kt and also diagnoses a significant fraction (18-25%) of the patients who could not be diagnosed with traditional methods.
BNGO Ratings Summary
BNGO Quant Ranking